Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

tors presented positive results from Phase 2 clinical trials of Amigal at the American College of Medical Genetics (ACMG) meeting. The data showed that Amigal was generally safe and well-tolerated at all doses evaluated and no drug-related serious adverse events were reported. In addition, Amigal increased the level of the enzyme deficient in Fabry patients in 24 of 26 study subjects, and in a majority of study subjects the treatment resulted in a reduction of kidney GL-3 as measured in urine.

Amicus, along with its partner Shire, has initiated discussions with the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) regarding its plans for Phase 3 clinical evaluation of Amigal. Amicus expects to complete these interactions and provide an update in the second half of 2008, and subject to the outcome of the discussions, the Company plans to initiate the Phase 3 clinical trial in the first half of 2009.

In parallel with the regulatory process, 23 of the original 26 patients continue to be treated with Amigal in the voluntary Phase 2 extension study to monitor long term safety and efficacy. In addition, the Company will evaluate modified doses and dose regimens in these 23 patients. Data from this extension study are expected to be available by Q1 2009, prior to finalization of the Phase 3 protocol.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic being developed for the treatment of Gaucher disease. At the ACMG meeting in March, clinical investigators presented full data from a 4 week Phase 2 study in Gaucher patients who switched from enzyme replacement therapy (ERT) with imiglucerase to the pharmacological chaperone Plicera. Results showed that Plicera was generally safe and well tolerated at all doses and increased target enzyme activity levels in a majority of patients. In the trial, GCase activity, as measured in white blood cells, was increased in 20 of the 26 pat
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Robert Harman, DVM, Founder and CEO ... proud to announce the relaunch of his highly informative blog, ... series called “ What are Stem Cells ?” Dr. ... straightforward foundation in the basics of stem cell therapy so ... right type of treatment when considering regenerative medicine. , A ...
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
(Date:7/10/2014)... July 10, 2014  Kainos Capital, a firm specializing ... announced that it has acquired the Slim-Fast brand from ... business. Terms of the transaction were not disclosed. ... replacement business that markets ready-to-drink shakes, powders, bars and ... and in the United Kingdom ...
(Date:7/10/2014)... July 10, 2014   Ceres, Inc . (Nasdaq: ... company, announced today financial results for the three months ... its business. Ceres reported that the company ... performance this growing season in Brazil, which concluded in ... company,s sorghum evaluation areas for part of the growing ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Kainos Capital Acquires Slim-Fast From Unilever 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... - Oncothyreon Inc. (Nasdaq: ONTY ) (TSX:ONY), ... therapeutic products for the treatment of cancer, today announced ... year end 2009 financial results on Wednesday, August 12, ... markets. Following the release, Oncothyreon,s management expects to discuss ...
... HARBIN, China, Aug. 6 /PRNewswire-Asia-FirstCall/ -- ... "the Company") (Nasdaq: CSKI ), a leading,fully ... of China ("PRC"), today announced the appointment of Mr.,William ... Board of Directors,("the Board") effective August 4, 2009. Mr. ...
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ... endocrine therapy and oncology, today announced that its President ... overview at the upcoming Canaccord Adams 29th Annual Global ... p.m. (eastern time) at the Intercontinental Hotel in Boston. ...
Cached Biology Technology:China Sky One Medical, Inc. Appoints New Independent Director 2China Sky One Medical, Inc. Appoints New Independent Director 3
(Date:7/10/2014)... genus Axinaea belongs to the large, mainly tropical ... ca. 5000 species in the family rely on bees for ... by other insects or vertebrates. The flowers of Axinaea ... flowers and the petals of the different species are pink, ... out based on the contrasting colours of their bulbous appendages. ...
(Date:7/10/2014)... Imagine the open ocean as a microbial megacity, teeming ... drop of water, hundreds of types of bacteria can ... of these ocean microbes have their own daily cyclesnot ... to wake up, commute, work, and eat at the ... sun. Light-loving photoautotrophsbacteria that need solar energy to help ...
(Date:7/10/2014)... company housed at NJIT,s business incubator, received a $1.4 ... surgeons will use to staunch bleeding during brain surgery. ... site, and the natural bio-polymer solutions in the gel ... 30 seconds. , The gel can shorten an ... into less time for the patient,s skull to be ...
Breaking Biology News(10 mins):Novel type of bird pollination mechanism discovered in South America 2New research finds ocean's most abundant organisms have clear daily cycles 2New research finds ocean's most abundant organisms have clear daily cycles 3A start-up at NJIT develops bleeding-control gel for brain surgery 2
... you ever met a cat that doesn't go crazy over ... the world don't respond to it at all, according to ... of Chemical & Engineering News, the weekly newsmagazine published by ... Catnip sensitivity is inherited, says Carolyn M. McDaniel, a veterinarian ...
... Florida researchers say they are a step closer to ... cancers before symptoms become apparent. , The findings, currently ... Sciences, involve introducing molecularly engineered strands of DNA into ... burst after they adhere to cancer proteins. , ...
... the gene responsible for controlling a first key step in ... in the journal Nature tomorrow (Thursday 27 October 2005). , ... take place once a sperm enters an egg, giving it ... reproducing animals. , The absence or mutation of this gene ...
Cached Biology News:Many cats unaffected by catnip, C&EN reports 2Scientists closer to new cancer detection method 2Scientists closer to new cancer detection method 3Scientists unpick genetics of first 15 minutes of life 2
Collected from 8-12 week old New Zealand or Californian rabbits. Aseptically collected and processed to minimize hemolytic activity. Pricing: $60/unit for 1 - 10 units...
Donor Goat Serum...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
Biology Products: